钠-葡萄糖协同转运蛋白 2 抑制剂：心力衰竭的非传统利尿剂。
SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.
机构信息
Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
出版信息
Cell Metab. 2020 Jul 7;32(1):13-14. doi: 10.1016/j.cmet.2020.06.014.
PMID:32640243
Abstract
Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.
摘要
最近的研究表明，无论糖尿病患者的状态如何，接受 SGLT2 抑制剂（SGLT2i）治疗的个体都能获得显著的心血管健康益处。但这些益处的潜在机制尚不清楚。最近，在《循环》杂志上，Griffin 等人（2020 年）报告了第一项研究依帕列净利尿作用的人体研究。
Zotero 插件